Elicio Therapeutics (ELTX) Return on Sales (2020 - 2023)

Elicio Therapeutics has reported Return on Sales for 4 years, with the latest figure at 0.43% in Q1 2023.

• For the quarter ending Q1 2023, Return on Sales fell 35.0% year-over-year to 0.43%; the trailing twelve-month figure through Mar 2023 stood at 0.43% (down 42.0% YoY), and the FY2022 full-year result was 0.12%, down 10.0% from the prior year.
• Return on Sales for Q1 2023 stood at 0.43%, down from 0.15% in the prior quarter.
• The five-year high for Return on Sales was 0.06% in Q4 2020, with the low at 0.54% in Q1 2021.
• Historically, Return on Sales has averaged 0.17% across 4 years, with a median of 0.13% in 2020.
• Annual changes were most pronounced in 2022 — Return on Sales jumped 45 bps — and 2023, when it tumbled 35 bps.
• Elicio Therapeutics' Return on Sales stood at 0.06% in 2020, then sank by 91 bps to 0.01% in 2021, then plunged by 2684 bps to 0.15% in 2022, then slumped by 188 bps to 0.43% in 2023.
• The last three Return on Sales figures came in at 0.43% (Q1 2023), 0.15% (Q4 2022), and 0.01% (Q3 2022), per Business Quant data.